Elliot Myers
Psychiatric/Mental Health · Carencro, LANPI 1528481587
Payments from drug & device makers
Across 202 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$982
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$467
- Alkermes, Inc.$440
- Axsome Therapeutics, Inc.$276
- Vanda Pharmaceuticals Inc.$229
- Neurocrine Biosciences, Inc.$214
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,69797%
- Education$1173%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 63 | $982 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $467 |
| Alkermes, Inc. | 21 | $440 |
| Axsome Therapeutics, Inc. | 13 | $276 |
| Vanda Pharmaceuticals Inc. | 10 | $229 |
| Neurocrine Biosciences, Inc. | 9 | $214 |
| E.r. Squibb & Sons, L.L.C. | 5 | $185 |
| Teva Pharmaceuticals USA, Inc. | 5 | $159 |
| Supernus Pharmaceuticals, Inc. | 6 | $126 |
| Lundbeck LLC | 6 | $100 |
| Novo Nordisk | 5 | $98 |
| Lilly USA, LLC | 6 | $90 |
| Otsuka America Pharmaceutical, Inc. | 4 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $64 |
| Johnson & Johnson | 3 | $59 |
| Idorsia Pharmaceuticals US Inc | 3 | $47 |
| Bayer | 2 | $40 |
| Amgen | 2 | $35 |
| Ardelyx, Inc. | 2 | $31 |
| Boehringer Ingelheim | 2 | $29 |
| Indivior Inc. | 1 | $27 |
| AstraZeneca | 1 | $17 |
| Novartis | 1 | $11 |
| Corium, LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$416
- VRAYLAR$118
- COBENFY$106
- ARISTADA INITIO$104
How this compares
$3,814 in reported general payments places this provider in the 75th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 33 | $49,208 |
| VraylarCariprazine Hcl | 25 | $35,877 |
| Invega SustennaPaliperidone Palmitate | 15 | $33,928 |
| OzempicSemaglutide | 29 | $27,336 |
| AuvelityDextromethorphan Hbr/Bupropion | 19 | $21,185 |
| JardianceEmpagliflozin | 20 | $13,263 |
| MounjaroTirzepatide | 12 | $12,927 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,138 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,856 |
| EliquisApixaban | 13 | $4,681 |
| Aripiprazole | 74 | $3,450 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $2,948 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 20 | $1,752 |
| Diclofenac Sodium | 24 | $1,125 |
| Gabapentin | 39 | $1,080 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $82 | $49,20833 claims |
| AbbVieVraylar | $982 | $35,87725 claims |
| Johnson & JohnsonInvega Sustenna | $59 | $33,92815 claims |
| Novo NordiskOzempic | $98 | $27,33629 claims |
| Axsome Therapeutics, Inc.Auvelity | $276 | $21,18519 claims |
| Lilly USA, LLCMounjaro, Humulin 70-30 | $90 | $13,42923 claims |
| Boehringer IngelheimJardiance | $29 | $13,26320 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $64 | $5,85612 claims |
| AstraZenecaSymbicort | $17 | $2,94813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Carencro
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
- Sattaria DilksLake Charles$57K
- Joe TaylorHammond$38K
- Lecy AlbaradoScott$34K
- Michelle DyerLake Charles$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.